A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Sponsored by Nuvectis Pharma, Inc.
About this study
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.
Enrolling at this location
University of Chicago
Chicago, Illinois
I'm interestedThis study also enrolls at 12 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.